Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer
暂无分享,去创建一个
Minglin Li | C. Deng | E. Rosen | P. Furth | Yongxian Ma | R. Lubet | C. Grubbs | E. Halama | Chu-Xia Deng | Eliot M Rosen | L. Jones | Ronald Lubet | Yongxian Ma | Clinton J Grubbs | Laundette P Jones | Priscilla A Furth | Ewa D Halama | Minglin Li
[1] M. Sporn. Chemoprevention of cancer. , 1993, Lancet.
[2] C. Deng,et al. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice , 2001, Oncogene.
[3] Ellen Warner,et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] K. Horwitz,et al. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? , 2000, The Journal of Steroid Biochemistry and Molecular Biology.
[5] S. Hilsenbeck,et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.
[6] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[7] Rachel Schiff,et al. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. , 2003, Breast.
[8] G. Chenevix-Trench,et al. Germ‐line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen‐responsive proteins and the predominance of progesterone receptor A , 2004, Genes, chromosomes & cancer.
[9] M. Osborne,et al. Influence of chemopreventive agents on estradiol metabolism and mammary preneoplasia in the C3H mouse , 1990, Steroids.
[10] V. Jordan,et al. Selective estrogen receptor modulation: concept and consequences in cancer. , 2004, Cancer cell.
[11] W. Lee,et al. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[12] K. Heimdal,et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study , 2000, The Lancet.
[13] M. Erdos,et al. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity , 2001, Oncogene.
[14] J. Garber,et al. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. , 2000, JAMA.
[15] J. Klijn,et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.
[16] R. Heyman,et al. Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. , 1999, Journal of the National Cancer Institute.
[17] R. Sutherland,et al. Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. , 1984, European journal of cancer & clinical oncology.
[18] A. Wellstein,et al. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Δ3 on estrogenic ligands with different intrinsic activity , 2004, Oncogene.
[19] Baljit Singh,et al. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer. , 2004, Cancer Genetics and Cytogenetics.
[20] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[21] J. Gustafsson,et al. Estrogen receptors α and β in the rodent mammary gland , 2000, Breast Cancer Research.
[22] Susan L Neuhausen,et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.
[23] J. Satagopan,et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.